Annette F. Okai

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 40 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15

Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction

Udomchai Techavipoo, Annette F. Okai, John Lackey et al. · Journal of Magnetic Resonance Imaging · 2009 · 27 citations

Medicine, Neurology, Neuroscience +17

Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?

Annette F. Okai, Srikanth Muppidi, Ritu Bagla et al. · Neurological Research · 2006 · 22 citations

Medicine, Neurology, Neuromuscular Disorders +10

Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial

Mitzi Williams, Annette F. Okai, Anne H. Cross et al. · Multiple Sclerosis and Related Disorders · 2023 · 14 citations · Full text

Life Sciences, Neurology, Neuroscience +9

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

Annette F. Okai, Lilyana Amezcua, Regina Berkovich et al. · Neurology and Therapy · 2019 · 12 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17